The Worst Peptide Vendors in 2026, According to Independent Lab Tests

Bottom line

Five vendors stand out in TitrateLab’s current testing records:

1. PeptAura, including Lumira and Welon
2. Peptides For Sale
3. Peptides 4 Research
4. Swiss Chems
5. Pharma Grade Peptides

This is not a list of vendors we dislike. It is not based on Reddit comments or affiliate rankings. It comes from published laboratory records.

PeptAura is here for repeated identity and dose failures across the Lumira and Welon brands it operates. The other four are here for repeated underfilling. Each had at least ten checkable amount tests. Each also had at least three severe underfills.

The records do not cover every vial these vendors sold. They do show repeated failures in the samples that were tested and published.

The five worst documented records

PeptAura, including Lumira and Welon

PeptAura operates the Lumira and Welon brands. It sells the products and controls the verification layer around them.

The current checkable record contains 104 identity results for Lumira and Welon. The labeled compound was not identified in 19 of them, or 18.3%.

The amount record is also poor. Twenty-six of 82 checkable amount tests measured more than 10% below the label. Five were at least 40% under. The worst measured result was 94.3% below the label on an NAD+ sample tested May 11, 2026. Read the certificate.

This is not only a bad batch story. PeptAura presents itself as the party solving the market’s trust problem. It operates the brands, publishes their certificates and tells buyers which results pass.

Our earlier PeptAura investigation documented a PeptAura verification page showing a pass for a batch whose own laboratory document failed its quantity specification. It also captured PeptAura’s own brand map and the founder’s statement that Lumira could only be purchased through PeptAura.

That investigation used 86 Lumira and Welon certificates available on August 2. The corpus has since grown. The current checkable snapshot contains 104 identity results and 19 identity failures.

Peptides For Sale

Peptides For Sale had the worst repeat underfill rate in the current screen.

All 14 of 14 checkable amount tests measured more than 10% below the label. Twelve measured at least 40% below it.

The worst result was an Ipamorelin sample tested February 27, 2025. It measured 79% below the label and 84.4% purity. Read the certificate.

Three more Ipamorelin samples measured between 73.6% and 76.8% below their labels. This is a repeated product record, not one close miss.

Peptides 4 Research

Peptides 4 Research had 18 underfilled results among 20 checkable amount tests. Three were severe.

Its worst result was a CJC-1295 sample tested May 7, 2025. It measured 52.2% below the label while still reporting 99.4% purity. Read the certificate.

That distinction matters. High purity does not mean the vial contains the amount printed on its label. A vial can contain clean peptide and still contain half of what was sold.

Two other CJC-1295 samples measured 46.2% and 41.4% below their labels. The failures repeated within the same product line.

Swiss Chems

Swiss Chems had 10 underfilled results among 11 checkable amount tests. Five were severe.

The worst was a CJC-1295 sample tested May 5, 2025. It measured 73% below the label and only 54.4% purity. Read the certificate.

The record is not limited to CJC-1295. Swiss Chems also had severe underfills documented for Ipamorelin and BPC-157.

The most recent checkable test in this vendor’s strict dose cohort was dated July 1, 2026. A later date does not erase the older failures. It does mean readers should check the current batch instead of treating this article as a permanent statement about every future vial.

Pharma Grade Peptides

Pharma Grade Peptides had 15 underfilled results among 22 checkable amount tests. Eleven were severe.

The worst CJC-1295 sample measured 89% below the label. A second CJC-1295 sample measured 88.4% below. Read the worst certificate.

The pattern reached other products. A PT-141 sample measured 85.9% below its label. A BPC-157 sample measured 85.4% below.

The name “Pharma Grade Peptides” is branding. The measured results are what matter.

Why these five

We did not combine purity, dose, identity and endotoxin into one mystery score.

PeptAura is the featured case because its record crosses several lines. It has repeated identity failures, repeated underfills and direct control over the brands and verification layer.

The other four came from the strict underfill screen. Each had at least ten checkable amount tests. Each had at least three results that measured 40% or more below the label.

Limitless Life Nootropics had a high material-underfill rate and would have placed near the top on that measure alone. It did not have a severe underfill in the current strict cohort. We therefore left it outside this five-vendor list.

Identity, dose and endotoxin findings remain separate. A company can perform badly on one and have little testing on another.

How we calculated it

The vendor screen used TitrateLab’s August 11, 2026 snapshot.

• 64,736 records passed the checkable-evidence rules.
• 1,171 duplicate records were removed.
• Every record was published and attributed to an identified vendor.
• A retained document needed an artifact or a direct verification source.
• Amount results at least 99% below the label were not treated as valid dose measurements. Those rows are normally identity failures.
• Material underfill means 10% or more below the label.
• Severe underfill means 40% or more below the label.
• A zero purity value is treated as a categorical identity failure, not a numerical purity result.
• Mean and median purity use only positive numerical results after identity passed, and always show their sample count.
• A vendor needed at least ten usable measurements to enter a rate ranking.
• The ranking also reduced the advantage created by tiny samples.

The broader community testing analysis explains why these failures need denominators. Most tested peptide samples did not fail identity. Serious failures were concentrated among a small number of vendors.

What this list does not prove

These tests were published voluntarily. They are not random purchases from every seller and every batch.

Some testing programs may receive more suspicious samples. Some vendors may test more often than others. A vendor’s rate in this database is not its share of all market sales.

The results do prove that the listed samples failed. Repeated results show a pattern in the observed record. They do not prove that every untested vial from the same vendor failed.

TitrateLab does not run these assays. Independent laboratories do. TitrateLab collects the reports, removes known duplicates and compares the results with the labels.

If a vendor believes a record is attributed incorrectly, it can send the original certificate and batch documentation through the contact page. Corrections should change the record when the evidence changes.

Check the batch, not the slogan

Words like “verified,” “pharma grade” and “99% pure” are cheap. A batch-specific laboratory result is harder to fake and easier to check.

Start with the peptide company review directory. Then open the certificates tied to the exact vendor and product. The COA verification guide explains what identity, purity and quantity can prove.

This list will change when the evidence changes. The five names above are the worst repeat records that met the stated rules in the August 11, 2026 snapshot.